Cas9 mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9). Cas9 functions as part of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest, and the Cas9 protein is employed to perform double-stranded DNA cleavage.

• Capped with CleanCap® AG cap analog, modified with 5-methoxyuridines

  Cap 1 structure with >95% capping efficiency for superior in vivo activity compared to Cap-0 mRNAs

  Manufactured with TriLink’s proprietary CleanScript® method to lower dsRNA for improved performance

  Ready to use in downstream mRNA applications and formulations

  Grade: RUO

This mRNA is capped using CleanCap® Reagent AG, TriLink's co-transciptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink’s CleanScript® method, polyadenylated, modified with 5-methoxyuridine, and optimised for mammalian systems. It mimics a fully processed mature mRNA.

CleanCap Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).

5-methoxyuridine (5moU) is a modified uridine that can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression.

CleanScript method is TriLink’s proprietary in vitro transcription process that is optimised to minimise dsRNA formation and increase mRNA activity in vivo.